{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T02:42:21Z","timestamp":1768272141338,"version":"3.49.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,4,11]],"date-time":"2021-04-11T00:00:00Z","timestamp":1618099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,11]],"date-time":"2021-04-11T00:00:00Z","timestamp":1618099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s12094-021-02604-x","type":"journal-article","created":{"date-parts":[[2021,4,11]],"date-time":"2021-04-11T13:02:21Z","timestamp":1618146141000},"page":"1967-1978","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Review of biomarker systems as an alternative for early diagnosis of ovarian carcinoma"],"prefix":"10.1007","volume":"23","author":[{"given":"A.","family":"Srivastava","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4256-5179","authenticated-orcid":false,"given":"S.","family":"Patidar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,11]]},"reference":[{"issue":"3","key":"2604_CR1","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/cmmi.499","volume":"7","author":"NL Adolphi","year":"2012","unstructured":"Adolphi NL, Butler KS, Lovato DM, et al. Imaging of Her2-targeted magnetic nanoparticles for breast cancer detection: comparison of SQUID-detected magnetic relaxometry and MRI. Contrast Med Mol Imaging. 2012;7(3):308\u201319. https:\/\/doi.org\/10.1002\/cmmi.499.","journal-title":"Contrast Med Mol Imaging"},{"issue":"1","key":"2604_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/path.2696","volume":"221","author":"AA Ahmed","year":"2010","unstructured":"Ahmed AA, Etemadmoghadam D, Temple J, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 2010;221(1):49\u201356. https:\/\/doi.org\/10.1002\/path.2696.","journal-title":"J Pathol"},{"issue":"5","key":"2604_CR3","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1074\/mcp.ra119.001362","volume":"18","author":"GD Barnabas","year":"2019","unstructured":"Barnabas GD, Bahar-Shany K, Sapoznik S, et al. Microvesicle proteomic profiling of uterine liquid biopsy for ovarian cancer early detection. Mol Cell Proteomics. 2019;18(5):865\u201375. https:\/\/doi.org\/10.1074\/mcp.ra119.001362.","journal-title":"Mol Cell Proteomics"},{"key":"2604_CR4","unstructured":"Chappelear A. About ovarian cancer: johns hopkins ovarian cancer center. In: Hopkinsmedicine.org. 2017. https:\/\/www.hopkinsmedicine.org\/kimmel_cancer_center\/cancers_we_treat\/ovarian\/about\/ (Accessed 15 Dec 2020)"},{"key":"2604_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.gore.2017.06.006","volume":"21","author":"M Chatterjee","year":"2017","unstructured":"Chatterjee M, Hurley LC, Tainsky MA. Paraneoplastic antigens as biomarkers for early diagnosis of ovarian cancer. Gynecol Oncol Rep. 2017;21:37\u201344. https:\/\/doi.org\/10.1016\/j.gore.2017.06.006.","journal-title":"Gynecol Oncol Rep"},{"issue":"3","key":"2604_CR6","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.ygyno.2011.06.002","volume":"122","author":"CH Clarke","year":"2011","unstructured":"Clarke CH, Yip C, Badgwell D, et al. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Gynecol Oncol. 2011;122(3):548\u201353. https:\/\/doi.org\/10.1016\/j.ygyno.2011.06.002.","journal-title":"Gynecol Oncol"},{"issue":"10","key":"2604_CR7","first-page":"3193","volume":"8","author":"BC Cooper","year":"2002","unstructured":"Cooper BC, Ritchie JM, Broghammer CL, et al. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res. 2002;8(10):3193\u20137.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2604_CR8","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1158\/1940-6207.capr-10-0195","volume":"4","author":"DW Cramer","year":"2011","unstructured":"Cramer DW, Bast RC, Berg CD, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res. 2011;4(3):365\u201374. https:\/\/doi.org\/10.1158\/1940-6207.capr-10-0195.","journal-title":"Cancer Prev Res"},{"issue":"3","key":"2604_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2217\/17520363.2.3.291","volume":"2","author":"PM Das","year":"2008","unstructured":"Das PM, Bast RC Jr. Early detection of ovarian cancer. Biomark Med. 2008;2(3):291\u2013303. https:\/\/doi.org\/10.2217\/17520363.2.3.291.","journal-title":"Biomark Med"},{"issue":"6","key":"2604_CR10","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1200\/jco.2003.02.022","volume":"21","author":"EP Diamandis","year":"2003","unstructured":"Diamandis EP, Scorilas A, Fracchioli S, et al. Human Kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol. 2003;21(6):1035\u201343. https:\/\/doi.org\/10.1200\/jco.2003.02.022.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2604_CR11","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.hoc.2018.07.003","volume":"32","author":"KM Elias","year":"2018","unstructured":"Elias KM, Guo J, Bast RC. Early detection of ovarian cancer. Hematol Oncol Clin North Am. 2018;32(6):903\u201314. https:\/\/doi.org\/10.1016\/j.hoc.2018.07.003.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"7","key":"2604_CR12","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/jnci\/92.7.564","volume":"92","author":"M Esteller","year":"2000","unstructured":"Esteller M. Promoter hypermethylation and brca1 inactivation in sporadic breast and ovarian tumors. J Nat Cancer Inst. 2000;92(7):564\u20139. https:\/\/doi.org\/10.1093\/jnci\/92.7.564.","journal-title":"J Nat Cancer Inst"},{"key":"2604_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep26952","volume":"6","author":"B Fazio","year":"2016","unstructured":"Fazio B, Andrea C, Foti A, et al. SERS detection of biomolecules at physiological pH via aggregation of gold nanorods mediated by optical forces and plasmonic heating. Scientif Rep. 2016;6:1\u201324. https:\/\/doi.org\/10.1038\/srep26952.","journal-title":"Scientif Rep"},{"issue":"2","key":"2604_CR14","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.ygyno.2017.07.13","volume":"147","author":"RT Fortner","year":"2017","unstructured":"Fortner RT, Damms-Machado A, Kaaks R. Systematic review: tumor-associated antigen autoantibodies and ovarian cancer early detection. Gynecol Oncol. 2017;147(2):465\u201380. https:\/\/doi.org\/10.1016\/j.ygyno.2017.07.13.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"2604_CR15","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1158\/1055-9965.epi-04-0404","volume":"14","author":"E Gorelik","year":"2005","unstructured":"Gorelik E. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomark Prev. 2005;14(4):981\u20137. https:\/\/doi.org\/10.1158\/1055-9965.epi-04-0404.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"3","key":"2604_CR16","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.ygyno.2018.03.050","volume":"149","author":"C Han","year":"2018","unstructured":"Han C, Bellone S, Siegel ER, et al. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. Gynecol Oncol. 2018;149(3):585\u201391. https:\/\/doi.org\/10.1016\/j.ygyno.2018.03.050.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"2604_CR17","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ygyno.2008.04.041","volume":"110","author":"LJ Havrilesky","year":"2008","unstructured":"Havrilesky LJ, Whitehead CM, Rubatt JM, et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol. 2008;110(3):374\u201382. https:\/\/doi.org\/10.1016\/j.ygyno.2008.04.041.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"2604_CR18","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1074\/mcp.r400006-mcp200","volume":"3","author":"IJ Jacobs","year":"2004","unstructured":"Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics. 2004;3(4):355\u201366. https:\/\/doi.org\/10.1074\/mcp.r400006-mcp200.","journal-title":"Mol Cell Proteomics"},{"issue":"3","key":"2604_CR19","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1111\/crj.12615","volume":"12","author":"X Jing","year":"2017","unstructured":"Jing X, Wei F, Li J, et al. Diagnostic value of soluble B7\u2013H4 and carcinoembryonic antigen in distinguishing malignant from benign pleural effusion. Clin Respir J. 2017;12(3):986\u201390. https:\/\/doi.org\/10.1111\/crj.12615.","journal-title":"Clin Respir J"},{"issue":"1","key":"2604_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.cll.2009.02.001","volume":"29","author":"K Kim","year":"2009","unstructured":"Kim K, Visintin I, Alvero AB, Mor G. Development and validation of a protein-based signature for the detection of ovarian cancer. Clin Lab Med. 2009;29(1):47\u201355. https:\/\/doi.org\/10.1016\/j.cll.2009.02.001.","journal-title":"Clin Lab Med"},{"issue":"9","key":"2604_CR21","doi-asserted-by":"publisher","first-page":"e44960","DOI":"10.1371\/journal.pone.0044960","volume":"7","author":"Y-W Kim","year":"2012","unstructured":"Kim Y-W, Bae SM, Lim H, Kim YJ, Ahn WS. Development of multiplexed bead-based immunoassays for the detection of early stage ovarian cancer using a combination of serum biomarkers. PLoS ONE. 2012;7(9):e44960. https:\/\/doi.org\/10.1371\/journal.pone.0044960.","journal-title":"PLoS ONE"},{"key":"2604_CR22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.addr.2015.03.009","volume":"89","author":"K Kong","year":"2015","unstructured":"Kong K, Kendall C, Stone N, Notingher I. Raman spectroscopy for medical diagnostics \u2014 From in-vitro biofluid assays to in-vivo cancer detection. Adv Drug Deliv Rev. 2015;89:121\u201334. https:\/\/doi.org\/10.1016\/j.addr.2015.03.009.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"2604_CR23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1757-2215-6-45","volume":"6","author":"S Lawicki","year":"2013","unstructured":"Lawicki S, B\u0119dkowska GE, Gacuta-Szumarska E, Szmitkowski M. The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors. J Ovarian Res. 2013;6(1):45. https:\/\/doi.org\/10.1186\/1757-2215-6-45.","journal-title":"J Ovarian Res"},{"key":"2604_CR24","unstructured":"Lockwood S. Ovarian Cancer. HealthyWomen. Published September 16, 2009. https:\/\/www.healthywomen.org\/condition\/ovarian-cancer (Accessed 3 Jan 2021)"},{"issue":"2","key":"2604_CR25","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ygyno.2005.12.011","volume":"102","author":"AE Lokshin","year":"2006","unstructured":"Lokshin AE, Winans M, Landsittel D, et al. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol Oncol. 2006;102(2):244\u201351. https:\/\/doi.org\/10.1016\/j.ygyno.2005.12.011.","journal-title":"Gynecol Oncol"},{"key":"2604_CR26","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1158\/0008-5472.CAN-06-0478","volume":"66","author":"AE Lokshin","year":"2006","unstructured":"Lokshin AE, Yurkovetsky Z, Nolen B, et al. Multimarker assay for early diagnosis of ovarian cancer. Cancer Res. 2006;66:155\u2013155.","journal-title":"Cancer Res"},{"issue":"1","key":"2604_CR27","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ygyno.2018.08.025","volume":"151","author":"M Lycke","year":"2018","unstructured":"Lycke M, Kristjansdottir B, Sundfeldt K. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index. Gynecol Oncol. 2018;151(1):159\u201365. https:\/\/doi.org\/10.1016\/j.ygyno.2018.08.025.","journal-title":"Gynecol Oncol"},{"issue":"27","key":"2604_CR28","doi-asserted-by":"publisher","first-page":"8279","DOI":"10.1007\/s00216-015-8946-1","volume":"407","author":"FM Lyng","year":"2015","unstructured":"Lyng FM, Traynor D, Ramos IRM, Bonnier F, Byrne HJ. Raman spectroscopy for screening and diagnosis of cervical cancer. Anal Bioanal Chem. 2015;407(27):8279\u201389. https:\/\/doi.org\/10.1007\/s00216-015-8946-1.","journal-title":"Anal Bioanal Chem"},{"issue":"3","key":"2604_CR29","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.trecan.2017.02.003","volume":"3","author":"IK Macdonald","year":"2017","unstructured":"Macdonald IK, Parsy-Kowalska CB, Chapman CJ. Autoantibodies: opportunities for early cancer detection. Trend Cancer. 2017;3(3):198\u2013213. https:\/\/doi.org\/10.1016\/j.trecan.2017.02.003.","journal-title":"Trend Cancer"},{"key":"2604_CR30","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.bspc.2016.11.015","volume":"33","author":"IP Mari\u00f1o","year":"2017","unstructured":"Mari\u00f1o IP, Blyuss O, Ryan A, et al. Change-point of multiple biomarkers in women with ovarian cancer. Biomed Signal Process Control. 2017;33:169\u201377. https:\/\/doi.org\/10.1016\/j.bspc.2016.11.015.","journal-title":"Biomed Signal Process Control"},{"issue":"3","key":"2604_CR31","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ygyno.2010.12.333","volume":"120","author":"JN McAlpine","year":"2011","unstructured":"McAlpine JN, El Hallani S, Lam SF, et al. Autofluorescence imaging can identify preinvasive or clinically occult lesions in fallopian tube epithelium: a promising step towards screening and early detection. Gynecol Oncol. 2011;120(3):385\u201392. https:\/\/doi.org\/10.1016\/j.ygyno.2010.12.333.","journal-title":"Gynecol Oncol"},{"issue":"19","key":"2604_CR32","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/jnci\/93.19.1458","volume":"93","author":"SC Mok","year":"2001","unstructured":"Mok SC, Chao J, Skates S, et al. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. JNCI J NatCancer Instit. 2001;93(19):1458\u201364. https:\/\/doi.org\/10.1093\/jnci\/93.19.1458.","journal-title":"JNCI J NatCancer Instit"},{"key":"2604_CR33","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2147\/ijwh.s197604","volume":"11","author":"Z Momenimovahed","year":"2019","unstructured":"Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Internat J Women\u2019s Health. 2019;11:287\u201399. https:\/\/doi.org\/10.2147\/ijwh.s197604.","journal-title":"Internat J Women\u2019s Health"},{"issue":"9","key":"2604_CR34","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1158\/1055-9965.epi-05-0980","volume":"15","author":"LE Moore","year":"2006","unstructured":"Moore LE, Fung ET, McGuire M, et al. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiol Biomark Prev. 2006;15(9):1641\u20136. https:\/\/doi.org\/10.1158\/1055-9965.epi-05-0980.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"1","key":"2604_CR35","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ygyno.2019.04.006","volume":"154","author":"RG Moore","year":"2019","unstructured":"Moore RG, Blackman A, Miller MC, et al. Multiple biomarker algorithms to predict epithelial ovarian cancer in women with a pelvic mass: Can additional makers improve performance? Gynecol Oncol. 2019;154(1):150\u20135. https:\/\/doi.org\/10.1016\/j.ygyno.2019.04.006.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"2604_CR36","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.ygyno.2007.10.017","volume":"108","author":"RG Moore","year":"2008","unstructured":"Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108(2):402\u20138. https:\/\/doi.org\/10.1016\/j.ygyno.2007.10.017.","journal-title":"Gynecol Oncol"},{"issue":"21","key":"2604_CR37","doi-asserted-by":"publisher","first-page":"7677","DOI":"10.1073\/pnas.0502178102","volume":"102","author":"G Mor","year":"2005","unstructured":"Mor G, Visintin I, Lai Y, et al. Serum protein markers for early detection of ovarian cancer. Proc Nat Acad Sci. 2005;102(21):7677\u201382. https:\/\/doi.org\/10.1073\/pnas.0502178102.","journal-title":"Proc Nat Acad Sci"},{"issue":"12","key":"2604_CR38","doi-asserted-by":"publisher","first-page":"e02826","DOI":"10.1016\/j.heliyon.2019.e02826","volume":"5","author":"T Muinao","year":"2019","unstructured":"Muinao T, Deka Boruah HP, Pal M. Multi-biomarker panel signature as the key to diagnosis of ovarian cancer. Heliyon. 2019;5(12):e02826. https:\/\/doi.org\/10.1016\/j.heliyon.2019.e02826.","journal-title":"Heliyon"},{"issue":"1","key":"2604_CR39","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12943-016-0536-0","volume":"15","author":"K Nakamura","year":"2016","unstructured":"Nakamura K, Sawada K, Yoshimura A, Kinose Y, Nakatsuka E, Kimura T. Clinical relevance of circulating cell-free microRNAs in ovarian cancer. Mol Cancer. 2016;15(1):12\u201334. https:\/\/doi.org\/10.1186\/s12943-016-0536-0.","journal-title":"Mol Cancer"},{"key":"2604_CR40","unstructured":"National Ovarian Cancer Coalition - NOCC Staff. Types and Stages - National Ovarian Cancer Coalition. Ovarian.org. Published 2021. https:\/\/www.ovarian.org\/about-ovarian-cancer\/what-is-ovarian-cancer\/types-a-stages. (Accessed 22 Jan 2021)"},{"issue":"8","key":"2604_CR41","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11912-019-0816-0","volume":"21","author":"DR Nebgen","year":"2019","unstructured":"Nebgen DR, Lu KH, Bast RC. Novel approaches to ovarian cancer screening. Curr Oncol Rep. 2019;21(8):12\u201353. https:\/\/doi.org\/10.1007\/s11912-019-0816-0.","journal-title":"Curr Oncol Rep"},{"issue":"6","key":"2604_CR42","doi-asserted-by":"publisher","first-page":"6391","DOI":"10.1016\/j.ajog.2008.12.042","volume":"200","author":"V Nosov","year":"2009","unstructured":"Nosov V, Su F, Amneus M, et al. Validation of serum biomarkers for detection of early-stage ovarian cancer. Am J Obstet Gynecol. 2009;200(6):6391\u20135. https:\/\/doi.org\/10.1016\/j.ajog.2008.12.042.","journal-title":"Am J Obstet Gynecol"},{"key":"2604_CR43","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.bios.2015.05.051","volume":"73","author":"MK Pal","year":"2015","unstructured":"Pal MK, Rashid M, Bisht M. Multiplexed magnetic nanoparticle-antibody conjugates (MNPs-ABS) based prognostic detection of ovarian cancer biomarkers, CA-125, \u03b2-2M and ApoA1 using fluorescence spectroscopy with comparison of surface plasmon resonance (SPR) analysis. Biosens Bioelectron. 2015;73:146\u201352. https:\/\/doi.org\/10.1016\/j.bios.2015.05.051.","journal-title":"Biosens Bioelectron"},{"key":"2604_CR44","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.talanta.2018.06.084","volume":"189","author":"M Paraskevaidi","year":"2018","unstructured":"Paraskevaidi M, Ashton KM, Stringfellow HF, et al. Raman spectroscopic techniques to detect ovarian cancer biomarkers in blood plasma. Talanta. 2018;189:281\u20138. https:\/\/doi.org\/10.1016\/j.talanta.2018.06.084.","journal-title":"Talanta"},{"issue":"15","key":"2604_CR45","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.clinbiochem.2015.04.005","volume":"48","author":"KM Patel","year":"2015","unstructured":"Patel KM, Tsui DWY. The translational potential of circulating tumour DNA in oncology. Clin Biochem. 2015;48(15):957\u201361. https:\/\/doi.org\/10.1016\/j.clinbiochem.2015.04.005.","journal-title":"Clin Biochem"},{"issue":"9","key":"2604_CR46","doi-asserted-by":"publisher","first-page":"838","DOI":"10.4065\/mcp.2010.0099","volume":"85","author":"LC Pelosof","year":"2010","unstructured":"Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc. 2010;85(9):838\u201354. https:\/\/doi.org\/10.4065\/mcp.2010.0099.","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"2604_CR47","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ultras.2013.05.014","volume":"54","author":"D Peng","year":"2014","unstructured":"Peng D, Xu T, Mason TJ, Wu W. A study of ovarian cancer biomarker amplification using ultrasound for early stage detection. Ultrasonics. 2014;54(2):451\u20134. https:\/\/doi.org\/10.1016\/j.ultras.2013.05.014.","journal-title":"Ultrasonics"},{"key":"2604_CR48","doi-asserted-by":"publisher","first-page":"BMIS7513","DOI":"10.4137\/bmi.s7513","volume":"6","author":"PF Pinsky","year":"2011","unstructured":"Pinsky PF, Zhu CS. Building multi-marker algorithms for disease prediction\u2013-the role of correlations among markers. Biomarker Insights. 2011;6:BMIS7513. https:\/\/doi.org\/10.4137\/bmi.s7513.","journal-title":"Biomarker Insights"},{"key":"2604_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/709049","volume":"22","author":"S Sarojini","year":"2012","unstructured":"Sarojini S, Tamir A, Lim H, et al. Early detection biomarkers for ovarian cancer. J Oncol. 2012;22:1\u201315. https:\/\/doi.org\/10.1155\/2012\/709049.","journal-title":"J Oncol"},{"issue":"3","key":"2604_CR50","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1158\/0008-5472.can-04-3550","volume":"66","author":"I Simon","year":"2006","unstructured":"Simon I, Zhuo S, Corral L, et al. B7\u2013H4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Can Res. 2006;66(3):1570\u20135. https:\/\/doi.org\/10.1158\/0008-5472.can-04-3550.","journal-title":"Can Res"},{"issue":"20","key":"2604_CR51","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1200\/jco.2004.03.091","volume":"22","author":"SJ Skates","year":"2004","unstructured":"Skates SJ, Horick N, Yu Y, et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15\u20133, CA 72\u20134, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol. 2004;22(20):4059\u201366. https:\/\/doi.org\/10.1200\/jco.2004.03.091.","journal-title":"J Clin Oncol"},{"key":"2604_CR52","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1177\/117727190700200011","volume":"2","author":"F Su","year":"2007","unstructured":"Su F, Lang J, Kumar A, et al. Validation of candidate serum ovarian cancer biomarkers for early detection. Biomark Insight. 2007;2:369\u201375.","journal-title":"Biomark Insight"},{"issue":"4","key":"2604_CR53","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s13277-011-0186-1","volume":"32","author":"J Tcherkassova","year":"2011","unstructured":"Tcherkassova J, Abramovich C, Moro R, et al. Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer. Tumor Biology. 2011;32(4):831\u20138. https:\/\/doi.org\/10.1007\/s13277-011-0186-1.","journal-title":"Tumor Biology"},{"issue":"4","key":"2604_CR54","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1158\/1078-0432.ccr-07-1569","volume":"14","author":"I Visintin","year":"2008","unstructured":"Visintin I, Feng Z, Longton G, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res. 2008;14(4):1065\u201372. https:\/\/doi.org\/10.1158\/1078-0432.ccr-07-1569.","journal-title":"Clin Cancer Res"},{"key":"2604_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-017-0500-7","volume":"9","author":"M Widschwendter","year":"2017","unstructured":"Widschwendter M, Zikan M, Wahl B, et al. The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer. Genome Med. 2017;9:1\u201334. https:\/\/doi.org\/10.1186\/s13073-017-0500-7.","journal-title":"Genome Med"},{"issue":"5","key":"2604_CR56","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.ultrasmedbio.2012.11.008","volume":"39","author":"H Xiang","year":"2013","unstructured":"Xiang H, Huang R, Cheng J, et al. Value of three-dimensional contrast-enhanced ultrasound in the diagnosis of small adnexal masses. Ultrasound Med Biol. 2013;39(5):761\u20138. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2012.11.008.","journal-title":"Ultrasound Med Biol"},{"issue":"52","key":"2604_CR57","doi-asserted-by":"publisher","first-page":"89811","DOI":"10.18632\/oncotarget.20688","volume":"8","author":"A Yokoi","year":"2017","unstructured":"Yokoi A, Yoshioka Y, Hirakawa A, et al. A combination of circulating miRNAs for the early detection of ovarian cancer. Oncotarget. 2017;8(52):89811\u201323. https:\/\/doi.org\/10.18632\/oncotarget.20688.","journal-title":"Oncotarget"},{"issue":"13","key":"2604_CR58","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1200\/jco.2008.19.2484","volume":"28","author":"Z Yurkovetsky","year":"2010","unstructured":"Yurkovetsky Z, Skates S, Lomakin A, et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol. 2010;28(13):2159\u201366. https:\/\/doi.org\/10.1200\/jco.2008.19.2484.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2604_CR59","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.currproblcancer.2018.06.001","volume":"43","author":"L Zhang","year":"2019","unstructured":"Zhang L, Chen Y, Wang K. Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis. Curr Probl Cancer. 2019;43(2):135\u201344. https:\/\/doi.org\/10.1016\/j.currproblcancer.2018.06.001.","journal-title":"Curr Probl Cancer"},{"issue":"16","key":"2604_CR60","doi-asserted-by":"publisher","first-page":"5882","DOI":"10.1158\/0008-5472.can-04-0746","volume":"64","author":"Z Zhang","year":"2004","unstructured":"Zhang Z, Bast RC, Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Can Res. 2004;64(16):5882\u201390. https:\/\/doi.org\/10.1158\/0008-5472.can-04-0746.","journal-title":"Can Res"},{"issue":"11","key":"2604_CR61","doi-asserted-by":"publisher","first-page":"e77853","DOI":"10.1371\/journal.pone.0077853","volume":"8","author":"H Zheng","year":"2013","unstructured":"Zheng H, Zhang L, Zhao Y, et al. Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PLoS ONE. 2013;8(11):e77853. https:\/\/doi.org\/10.1371\/journal.pone.0077853.","journal-title":"PLoS ONE"},{"key":"2604_CR62","doi-asserted-by":"publisher","first-page":"5615","DOI":"10.1007\/978-3-319-67199-4_101940","volume":"4","author":"G Papanikolaou","year":"2018","unstructured":"Papanikolaou G, Gkouvatsos K, Pantopoulos K. Transferrin. Encycloped Signal Mole . 2018;4:5615\u201323. https:\/\/doi.org\/10.1007\/978-3-319-67199-4_101940.","journal-title":"Encycloped Signal Mole"},{"key":"2604_CR63","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1515\/cclm.2002.208","volume":"5","author":"J Robbins","year":"2002","unstructured":"Robbins J. Transthyretin from discovery to now. Clin Chem Lab Med. 2002;5:40\u2013112. https:\/\/doi.org\/10.1515\/cclm.2002.208.","journal-title":"Clin Chem Lab Med"},{"key":"2604_CR64","unstructured":"Wikipedia Contributors. ApoA-1 Milano. Wikipedia. Published December 30, 2020. https:\/\/en.wikipedia.org\/wiki\/ApoA-1_Milano#:~:text=5%20Subsequent%20Development-,Discovery,small%20village%20in%20northern%20Italy. (Accessed 28 Jan 2021)"},{"issue":"1","key":"2604_CR65","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ygyno.2014.03.553","volume":"134","author":"JB Smith","year":"2014","unstructured":"Smith JB, Stashwick C, Powell DJ. B7\u2013H4 as a potential target for immunotherapy for gynecologic cancers: a closer look. Gynecol Oncol. 2014;134(1):181\u20139. https:\/\/doi.org\/10.1016\/j.ygyno.2014.03.553.","journal-title":"Gynecol Oncol"},{"issue":"4\u20135","key":"2604_CR66","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1387\/ijdb.103216dr","volume":"55","author":"D Ribatti","year":"2011","unstructured":"Ribatti D. From the discovery of vascular endothelial growth factor to the introduction of Avastin in clinical trials - an interview with Napoleone Ferrara. Int J Dev Biol. 2011;55(4\u20135):383\u20138. https:\/\/doi.org\/10.1387\/ijdb.103216dr.","journal-title":"Int J Dev Biol"},{"key":"2604_CR67","unstructured":"Simmons AR, Baggerly K, Bast RC. The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas. Oncology (Williston Park, NY). 2013;27(6):548\u2013556. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4085777\/. (Accessed 28 Jan 2021)"},{"key":"2604_CR68","unstructured":"Wikipedia Contributors. Osteopontin. Wikipedia. Published January 4, 2021. https:\/\/en.wikipedia.org\/wiki\/Osteopontin. (Accessed 28 Jan 2021)"},{"issue":"4","key":"2604_CR69","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2217\/17520363.1.4.513","volume":"1","author":"N Scholler","year":"2007","unstructured":"Scholler N, Urban N. CA125 in ovarian cancer. Biomark Med. 2007;1(4):513\u201323. https:\/\/doi.org\/10.2217\/17520363.1.4.513.","journal-title":"Biomark Med"},{"key":"2604_CR70","unstructured":"Wikipedia Contributors. Carcinoembryonic antigen. Wikipedia. Published January 2, 2021. https:\/\/en.wikipedia.org\/wiki\/Carcinoembryonic_antigen. (Accessed 28 Jan 2021)"},{"issue":"1","key":"2604_CR71","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2353\/ajpath.2006.050601","volume":"168","author":"M Sanchez-Carbayo","year":"2006","unstructured":"Sanchez-Carbayo M, Socci ND, Lozano JJ, Haab BB, Cordon-Cardo C. Profiling bladder cancer using targeted antibody arrays. Am J Pathol. 2006;168(1):93\u2013103. https:\/\/doi.org\/10.2353\/ajpath.2006.050601.","journal-title":"Am J Pathol."}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-021-02604-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-021-02604-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-021-02604-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T21:23:40Z","timestamp":1630013020000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-021-02604-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,11]]},"references-count":71,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["2604"],"URL":"https:\/\/doi.org\/10.1007\/s12094-021-02604-x","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,11]]},"assertion":[{"value":"15 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}